SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

TuHURA Biosciences, Inc./NV
Date: Sept. 25, 2025 · CIK: 0001498382 · Accession: 0000000000-25-010492

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
September 25, 2025
Author
James Bianco
Form
UPLOAD
Company
TuHURA Biosciences, Inc./NV

Letter

September 25, 2025 James Bianco Chief Executive Officer TuHURA Biosciences, Inc. 10500 University Center Drive, Suite 110 Tampa, FL 33612 Re:TuHURA Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted September 22, 2025 CIK No. 0001498382 Dear James Bianco: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Curt P. Creely, Esq.

Show Raw Text
September 25, 2025
James Bianco
Chief Executive Officer
TuHURA Biosciences, Inc.
10500 University Center Drive, Suite 110
Tampa, FL 33612
Re:TuHURA Biosciences, Inc.
Draft Registration Statement on Form S-1
Submitted September 22, 2025
CIK No. 0001498382
Dear James Bianco:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement and non-public draft
submission on EDGAR at least two business days prior to the requested effective date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Curt P. Creely, Esq.